Outcomes of Delayed HLA Haploidentical Transplantation with Peripheral Blood Allografts for High-Risk Patients with Severe Aplastic Anemia
Revista de Investigación Clínica · 2025
DOI: 10.24875/ric.25000012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Revista de Investigación Clínica, 2025. Verfasst von Jaime-Pérez José C und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Internal Medicine Division, Dr. José Eleuterio González University Hospital; and School of Medicine, Universidad Autónoma d…. Hauptthemen laut MEDLINE: Anemia, Aplastic, Transplantation, Haploidentical, Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
UNASSIGNED: Background: In severe aplastic anemia (AA) sibling haploidentical hematopoietic stem cell transplantation (haplo-HSCT) from the peripheral blood (PB) is an alternative when an HLA-identical donor is unavailable.
Objective
To document the results of haplo-HSCT in high-risk severe AA.
Methods
Twelve patients with severe AA who failed medical therapy and received a haploidentical PB unmanipulated HSCT from a sibling at an academic medical center were analyzed. Overall (OS) and event-free survival (EFS) were determined by Kaplan-Meier analyses.
Results
The median between AA diagnosis and haplo-HSCT was 6.5 months (2-19). Median of age was 25.5 (range, 4-54) years; 9 (75%) recipients were males, and all suffered multiple treatment failures. Anti-thymocyte globulin-based conditioning regimens were given to 6 (50%) patients. Five (41.7%) HSCT were ambulatory. Infections developed in all patients and graft failure in 9 (75%). 2-year OS was 52% and EFS 25%. High transfusion burden, treatment failure, and donors > 30 years had no effect on OS (p = 0.518, p = 0.984, p = 0.321) or EFS (p = 0.113, p = 0.692, p = 0.199). Patient's age > 40 was not significant for survival (p = 0.395). Three of five evaluable patients developed acute graft-versus-host disease that progressed to chronic disease.
Conclusions
Delayed PB haplo-HSCT for severe AA offered poor outcomes. Rapid referral for HSCT is critically required. (Rev Invest Clin. 2025;77(1):26-33).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Internal Medicine Division, Dr. José Eleuterio González University Hospital; and School of Medicine, Universidad Autónoma de Nuevo León, Monterrey, Mexico.
Zitieren
APA
José C, J. P., Mariana, G. T., Renata V, B. L., Olga G, C. R., César H, G. A., & David, G. A. (2025). Outcomes of Delayed HLA Haploidentical Transplantation with Peripheral Blood Allografts for High-Risk Patients with Severe Aplastic Anemia. Revista de Investigación Clínica. https://doi.org/10.24875/ric.25000012
Vancouver
José C JP, Mariana GT, Renata V BL, Olga G CR, César H GA, David GA. Outcomes of Delayed HLA Haploidentical Transplantation with Peripheral Blood Allografts for High-Risk Patients with Severe Aplastic Anemia. Revista de Investigación Clínica. 2025. doi:10.24875/ric.25000012
BibTeX
@article{JosC2025,
author = {José C, Jaime-Pérez and Mariana, González-Treviño and Renata V, Barragán-Longoria and Olga G, Cantú-Rodríguez and César H, Gutiérrez-Aguirre and David, Gómez-Almaguer},
title = {Outcomes of Delayed HLA Haploidentical Transplantation with Peripheral Blood Allografts for High-Risk Patients with Severe Aplastic Anemia},
journal = {Revista de Investigación Clínica},
year = {2025},
doi = {10.24875/ric.25000012}
}
EUVIMED